Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804494 | 0.80 | CHRNB4 (0.37) | BCHEF12CHRNB4CHRNA3HTR2C | |
| SCHEMBL1804493 | 0.80 | CHRNB4 (0.37) | BCHEF12CHRNB4CHRNA3HTR2C | |
| SCHEMBL1804490 | 0.80 | CHRNB4 (0.37) | BCHEF12CHRNB4CHRNA3HTR2C | |
| SCHEMBL19696035 | 0.80 | CHRNB4 (0.39) | MEN1GAAKMT2ACHRNB4CHRNA3 | |
| SCHEMBL19122664 | 0.80 | CHRNB4 (0.39) | MEN1GAAKMT2ACHRNB4CHRNA3 | |
| SCHEMBL24138192 | 0.80 | CHRNB4 (0.39) | MEN1GAAKMT2ACHRNB4CHRNA3 | |
| SCHEMBL17075140 | 0.79 | PRCP (0.37) | BCHEHTR2C | |
| SCHEMBL17075095 | 0.77 | F12 (0.33) | BCHEF12ALDH1A1F2 | |
| SCHEMBL12181445 | 0.76 | SIGMAR1 (0.34) | BCHEF12HTR2CF2 | |
| SCHEMBL12620830 | 0.76 | SIGMAR1 (0.47) | F12MEN1ALDH1A1KMT2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | BCHE 865/4885F12 38/4885MEN1 1376/4885 |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | BCHE 757/4885F12 64/4885MEN1 1818/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | BCHE 775/4885F12 64/4885MEN1 1841/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | BCHE 766/4885F12 39/4885MEN1 1233/4885 |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | BCHE 775/4885F12 64/4885MEN1 1841/4885 |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | BCHE 746/4885F12 61/4885MEN1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.